Physician profile
Scott Thompson
NPI 1962714964
$13,415.50
in general payments reported to CMS, 2019-2025
49 companies · $1,230 in 2025
The $1,230 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,960 · 2022: $1,196 · 2023: $2,711 · 2024: $3,318 · 2025: $1,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,259.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,163.92 | 2021-2025 | Darzalex, Tecvayli, Carvykti |
| E.R. Squibb & Sons, L.L.C. | $1,246.18 | 2021-2025 | Opdivo, Reblozyl, Pomalyst |
| Astrazeneca Pharmaceuticals Lp | $951.86 | 2021-2024 | Calquence, Enhertu |
| Glaxosmithkline, LLC. | $524.16 | 2021-2023 | Zejula, Jemperli, Blenrep |
| Celgene Corporation | $494.28 | 2021-2025 | Reblozyl, Opdivo |
| Exelixis INC. | $483.32 | 2021-2024 | Cabometyx |
| Merck Sharp & Dohme LLC | $461.69 | 2021-2024 | Lynparza, Keytruda |
| Pfizer INC. | $457.07 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $402.01 | 2021-2024 | Libtayo |
| Astellas Pharma US INC | $384.08 | 2021-2025 | Padcev, Xospata, Vyloy |
| Gilead Sciences, INC. | $355.91 | 2022-2024 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $328.41 | 2023-2024 | Fruzaqla, Iclusig |
| Janssen Scientific Affairs, LLC | $313.33 | 2023-2024 | Imbruvica, Talvey, Tecvayli |
| Lilly USA, LLC | $282.91 | 2021 | |
| Secura Bio, INC. | $217.73 | 2024 | Copiktra |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.